Acquired Pure Megakaryocytic Aplasia

Last update 01 Nov 2024

Basic Info

Synonyms

Acquired pure megakaryocytic aplasia, 获得纯巨核细胞再生障碍性贫血

Introduction-

100 Clinical Results associated with Acquired Pure Megakaryocytic Aplasia

100 Translational Medicine associated with Acquired Pure Megakaryocytic Aplasia

0 Patents (Medical) associated with Acquired Pure Megakaryocytic Aplasia

Literatures (Medical) associated with Acquired Pure Megakaryocytic Aplasia

01 Dec 2010·Turkish Journal of HematologyQ4 · MEDICINE

Acquired pure megakaryocytic aplasia successfully treated with cyclosporine

Q4 · MEDICINE

ArticleOA

Author: Ibrahim, Firyal ; Yassin, Mohammed ; Baden, Hussein ; Ayoubi, Hanadi El ; Khinji, Aisha Al ; Negm, Riham Hassan ; Taha, Ruba Yasin ; Omri, Halima El ; Hijji, Ibrahim Al

Acquired pure megakaryocytic aplasia is a rare hematological disorder characterized by thrombocytopenia with absent or markedly reduced megakaryocytes in the bone marrow. We report a case of a 25-year-old male diagnosed as acquired pure megakaryocytic aplasia. Treatment with prednisone and intravenous immunoglobulin failed, but he was successfully treated with cyclosporine, with complete remission after 90 days and normal platelet count maintained thereafter.

01 Jul 2007·American Journal of HematologyQ1 · MEDICINE

Acquired pure megakaryocytic aplasia: Report of a single case treated with mycophenolate mofetil

Q1 · MEDICINE

Review

Author: Stuart Hinton ; Robert Belt ; Jagdish Nachnani ; Deepti Bulchandani

AbstractAcquired pure megakaryocytic aplasia (APMA) is a rare disorder in the field of hematological diseases. We report the case of a patient with APMA treated with mycophenolate mofetil and review the literature associated with this. Until today, very few cases of APMA have been reported and the disease etiology still seems to be unclear. There have been no reported cases of treatment of APMA treated with mycophenolate mofetil. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.

01 Jun 2004·European Journal of HaematologyQ3 · MEDICINE

Acquired pure megakaryocytic aplasia: a separate haematological disease entity or a syndrome with multiple causes?

Q3 · MEDICINE

Article

Author: P. Felderbauer ; N. Ansorge ; F. Schmitz ; K. Bulut ; J. E. Baier ; D. Mattern ; W. E. Schmidt ; A. Schmitt-Graeff ; P. R. Ritter

Abstract:We report the case of a patient with acquired pure megakaryocytic aplasia. Until today, less than 20 cases of acquired pure megakaryocytic aplasia have been reported and the disease aetiology still seems to be unclear. This report summarizes the published data concerning possible aetiologies, treatment options and outcome of patients with acquired pure megakaryocytic aplasia. Furthermore, this case report presents an example for a possible disease progression.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Acquired Pure Megakaryocytic Aplasia

Basic Info

Related

Analysis